Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Nooka, Ajay K
  • Mian, Hira
  • Lee, Cindy
  • Rodríguez-Otero, Paula
  • Kumar, Shaji
  • Einsele, Hermann
  • Vishwamitra, Deeksha
  • Vieyra, Diego
  • Kane, Colleen
  • Kosh, Michele
  • Masterson, Tara J
  • Heuck, Christoph
  • Kansagra, Ankit
  • Moreau, Philippe

publication date

  • November 5, 2024

published in